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Interstitial cystitis or bladder pain syndrome (IC/BPS) is a disease of unknown etiology manifested with
bladder pain and frequency urgency symptoms. Although several pathophysiologic mechanisms have
been proposed, the underlying mechanism of IC/BPS is still unclear. Accumulated evidence supports that
IC/BPS is actually a spectrum of clinical phenomena that involves several different genes and environ-
mental factors. Heterogeneous syndromes are seen in patients with IC/PBS, which suggests that the
disease should be classiﬁed into different subtypes. Abnormal expressions of several bladder epithelial
markers, including mast cells, epithelial differentiation proteins, cell membrane proteins, neurotrans-
mitters, and cytokines, are present in IC/BPS. This review discusses the possible biomarkers that may play
crucial roles in IC/BPS, and especially focuses on those that have the potential to be used as biomarkers
for prognosis and for the determination of the best treatment for patients.
Copyright © 2016, Taiwan Urological Association. Published by Elsevier Taiwan LLC. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Interstitial cystitis or bladder pain syndrome (IC/BPS) is a
chronic condition of unknown etiology that is characterized by
clinical symptoms of urinary urgency/frequency and results in
recurring discomfort or pain in the bladder and pelvic region.
Although many theories have been proposed, there is still a lack of
consensus regarding the pathophysiology of IC/BPS. No single test
can be used to diagnose IC/BPS, and therefore a combination of
several diagnostic tests is required to rule out other diseases and
conﬁrm the presence of IC/BPS.
Currently, the diagnosis of IC/BPS is based on the presence of
pain related to the bladder that is normally accompanied by fre-
quency and urgency of urination, and the patient should be absent
of other diseases that could cause the same symptoms. Although
several pathophysiologic mechanisms have been proposed, the
underlying mechanism of IC/BPS is still unclear, and universally
accepted diagnostic criteria for the disease are still under devel-
opment. As many different disorders may cause the same symp-
toms as those present in IC/BPS, we need to discover reliableBuddhist Tzu Chi General
aiwan.
ociation. Published by Elsevier Tamarkers that can not only help to correctly diagnose the disease,
but more importantly, to identify a speciﬁc treatment that is best
for patients.2. Discovery of biomarkers for IC/BPS to improve treatment
Biomarkers provide a powerful approach to understanding the
progress of a disease. For the best biomarkers, it should be easy to
perform tests that are accurate tools for diagnosis and prognosis.
Accumulated evidence supports that IC/BPS is actually a spectrum
of clinical phenomena that involves several different genes and
environmental factors. In order to validate the best biomarker(s), it
is necessary to determine diagnostic criteria that can identify
different subsets of patients, and certain biomarkers can be used to
screen patients who will respond to a speciﬁc treatment or to
measure the outcome of a treatment. Heterogeneous syndromes
are seen in patients with IC/PBS, which suggests that the disease
should be classiﬁed into different subtypes. For example, Bouche-
louche and Nordling1 concluded that the disease can be classiﬁed
into a classic (ulcer) type and a non-nuclear type, and different
approaches may be required to treat these two types of patient. In
2008, the European Society for the Study of Interstitial Cystitis
(ESSIC) proposed a new classiﬁcation system,2 which classiﬁes the
disease into more different subtypes/stages. When a widely
acceptable classiﬁcation system is developed, identifying markersiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
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molecular mechanism of the disease and further improve practical
clinical treatment.
3. Pathogenesis of IC/BPS
It is now generally agreed that infection is not a direct etiology of
IC/BPS, as several studies have failed to detect bacterial DNA in
patients with IC/BPS.3,4 It is known that a defect in bladder uro-
thelial permeability is associated with the pathogenesis of IC/BPS,
but the mechanism that causes urothelial disruption is still un-
known. It is possible that a bacterial endotoxin, such as lipopoly-
saccharide, might cause urothelial damage and indirectly
contribute to the development of the disease. Recent studies in
humans with IC/BPS and in animal models of IC have highlighted
directions for better treatment of the disease.
Activation and increased numbers of mast cells in the bladder
urothelium are seen in patients with IC/BPS.5 Mast cells secrete
several inﬂammatory mediators, including substance P and nerve
growth factor (NGF), which are associated with the proliferation of
nerve ﬁbers.6,7 In addition, mast cells also release cytokines and
other proinﬂammatory and nociceptive mediators.8 Study has also
shown that stress increases IC/BPS symptoms in patients,9 which
may be due to stress-induced neurogenic chronic inﬂammation
that causes overactivation of the sympathetic nervous system. This
review discusses the possible biomarkers that may play crucial
roles in IC/BPS, and especially focuses on those that have the po-
tential to be used as biomarkers for prognosis and for the deter-
mination of the best treatment for patients.
4. Markers in bladder tissue
4.1. Mast cells
Several reports have indicated that bladder specimens of pa-
tients with IC/BPS show increased numbers of inﬁltrated mast
cells.5,10e13 Other studies have also shown that mast cells are found
both in the epithelium and in bladder washings of patients with IC/
BPS, but not in normal individuals.12,14 This evidence suggests that
the disease is mediated by the immune system, and the abnor-
malities are possibly caused by dysregulation of the inﬂammatory
response. In addition to the increased number of mast cells in the
bladder in IC/BPS, the mast cells are mainly activated, as they are
partially or completely degranulated.11 Thus, the increased cell
number and activation of mast cells in the bladder suggests that
mucosal mast cells are one of the main events involved in the eti-
ology of IC/BPS.
Although it is now known that there are increased numbers and
increased activation of mast cells in the bladder of patients with IC/
BPS, the cell count in tissue and the percentage of activated mast
cells are signiﬁcantly inﬂuenced by sample processing. Therefore, a
standardized method and a certain number of control individuals
are required to validate the use of mast cells as a biomarker of IC/
BPS.
4.2. Bladder urothelial defects
Primary urothelial lining defects are thought to play an
important role in IC/BPS.15 Urothelial defects are signiﬁcantly
associated with chronic inﬂammation, and increased urothelial
apoptosis may be the causative factor of the disease.16 Several
studies have also shown that decreased tight junction protein
zonula occludens-1 expression occurs in IC/BPS, suggesting that
urothelial barrier defects may lead to increased urothelial
leakage and painful bladder symptoms.17e19 Several studies havelinked overactive bladder (OAB) and IC/BPS to chronic inﬂam-
mation, showing that the levels of bladder and urinary NGF, cy-
tokines, and serum C-reactive protein are elevated in both
patients with OAB and those with IC/BPS.20e25 Although it has
been suggested that OAB and IC/BPS might share a common
pathway, our recent study demonstrated that although mast cell
inﬁltration was found in both diseases, abnormal urothelial
barrier function only occurred in patients with IC/BPS, and not in
those with OAB.26
Proper function of the urothelium requires normal epithelial
integrity, which relies on intercellular adhesion molecules and a
layer of molecular components on the apical surface of the uro-
thelium. E-cadherin is one of the intercellular junction proteins that
have been suggested to be involved in the barrier function of the
urothelium. The role of E-cadherin in the pathophysiology of IC/
BPSS remains controversial. Earlier studies demonstrated elevated
E-cadherin in the bladder of patients with IC/BPS, and it has been
suggested that this is due to adaptation to increased bladder
permeability.27,28 However, recent studies from our group and
others have shown decreased or abnormal expression of E-cad-
herin in IC/BPS.16,19,26 The apical surface of the urothelium is coated
with a layer of glycoproteins, proteoglycans, and glycolipids, with a
superﬁcial proportion of glycosaminoglycans (GAGs) on the top of
the layer.29 The GAG or mucin layer is thought to act as a nonspe-
ciﬁc anti-adherence factor and as a defense mechanism against
infection,30,31 and several lines of evidence support that surface
mucosal and GAG dysfunction contribute to IC/PBS.32 Since these
studies, GAG replenishment therapy has been under develop-
ment.33 Although GAGs in the bladder urothelium have an impor-
tant role, the mucin GAG-layer lining is constituted by a group of
different glycoproteins, proteoglycans, and other molecules, and
further studies to identify the key molecules in IC/BPS will help to
improve the efﬁcacy of treatment and identify biomarkers of the
disease.
5. Serum and urinary biomarkers for OAB and IC/BPS
Serum and urinary cytokines, chemokines, and other infor-
matory mediators are potential molecules that could be devel-
oped as useful markers for IC/BPS as they are noninvasive
predictors. Cytokines and chemokines have crucial roles in the
pathogenesis of several chronic inﬂammatory diseases. As
bladder inﬂammation is one of the major causes of IC/BPS, it is
likely that the biomarkers from serum and urine have a prog-
nostic role and can serve as tools for the selection of suitable
therapeutic agents for treatment.
5.1. Cytokines
Increased levels of cytokines and chemokines have been found
in the urine of patients with IC/BPS. Studies by Erickson et al34 and
Sakthivel et al35 found that several proinﬂammatory mediators,
such as interleukin-6 (IL-6) and CXC chemokines, were increased in
urinary and serum samples of patients with IC/BPS. Lamale and
coworkers36 proposed the use of a combination of methylhistamine
and IL-6 as a sensitive and speciﬁc marker for IC/BPS. A study by
Ogawa and colleagues37 also conﬁrmed upregulation of several
CXCR3 binding chemokines in patients with ulcerative IC/BPS.
Controversial results have been reported for other cytokines,
including IL-2, IL-8, interferon-g, and tumor necrosis factor-a,
which were only found to be increased in patients in some earlier
studies.34,38,39 Our recent study revealed that the serum IL-1b, IL-6,
tumor necrosis factor-a, and IL-8 levels were signiﬁcantly higher in
the serum of patients with IC/BPS than in control patients
(Table 1).40
Table 1
Expression of serum interleukin (IL)-1b, IL-6, tumor necrosis factor (TNF-a) and IL-8
in interstitial cystitis or bladder pain syndrome (IC/PBS) patients and controls.
Controls (n ¼ 26) IC/PBS (n ¼ 30) p
Gender F:16 M:10 F: 26 M: 4
Age (y) 32.36 ± 1.56 (22e55) 50.57 ± 2.68 (24e86) <0.001
IL-1b (pg/mL) 1.64 ± 0.47 (0.00e6.08) 6.45 ± 0.71 (2.77e23.96) <0.001
IL-6 (pg/mL) 0.79 ± 0.21 (0.00e3.67) 1.52 ± 0.24 (0.00e6.14) <0.001
TNF-a (pg/mL) 0.91 ± 0.17 (0.00e4.64) 2.63 ± 0.60 (0.62e13.70) <0.001
IL-8 (pg/mL) 1.45 ± 0.21 (0.00e4.09) 3.23 ± 0.48 (0.00e15.08) <0.001
Data are presented as mean ± standard error (minemax).
F ¼ female; M ¼ male.
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In patients with IC/PBS, neurotrophins, including NGF,
neurotrophin-3, and glial-cell-derived neurotrophic factor, have
been detected in the urine.41 NGF is a small secreted protein that
induces differentiation and survival of target neurons. NGF has
been shown to play a role in altered lower urinary tract function.
Here, NGF acts as a chemical mediator in C-ﬁber afferents that may
regulate the change in urinary bladder function.42,43 The levels of
several neurotrophic factors, including NGF, increase in the bladder
after spinal cord injury,42,44 and NGF has been found to increase in
the lumbosacral spinal cord and dorsal root ganglia after spinal
cord injury in a rat model.45 Patients with lower urinary tract dis-
eases, including IC/BPS23e25,41,46 and bladder outlet obstruction,47
have been found to have increased NGF levels in the urine and/or
bladder tissue.
In the bladder, NGF is expressed in the urothelial cells and
smooth muscle.48 Normally, NGF exists in the afferent nerves and
ganglia of the bladder wall and is responsible for the normal
sensation of bladder distention and conduction of abnormal sen-
sory input.48 NGF is also released by mast cells.49 In a transgenic
mouse model, chronic NGF overexpression in the bladder led to
neuronal hyperinnervation, pelvic sensitivity, and changes in uri-
nary bladder function.50
Serum NGF levels have been found to increase in several sys-
temic diseases, including allergic diseases, autoimmune diseases,
and psychosocial stress,51e53 and therefore analysis of both urinary
and serum NGF in patients with IC/BPS provides insight into the
development of the disease. In samples of patients with IC/BPS,
increased levels of NGF have been noted in the urine23,24,41,46 and
bladder tissue.25 Our recent study showed that the serumNGF level
of IC/BPS patients was elevated, while the increased serum NGF
level was not correlated with the urinary NGF level and was not
related to the severity of IC/BPS (Fig. 1).54 These ﬁndings suggest
that NGF is associated with bladder function, and elevated urinary
NGF levels reﬂect that chronic inﬂammation is occurring in the
urinary bladder of IC/BPS patients.Fig. 1. Nerve growth factor (NGF)-immunoreactivity in the bladder of patients with intersti
submucosal and urothelial cells at baseline (A) 200 and (B) 400. NGF staining in the coNGF has been suggested to act as a local stress mediator in
perceived stress and allergy, and increased NGF leads to deterio-
rating allergic inﬂammation in stress-induced worsening of allergic
inﬂammation.55 Stress has been shown to be involved in the
pathogenesis of IC/BPS,9 and has also been found to induce NGF
expression in the urinary bladder in an animalmodel.56 The urinary
NGF level has been shown to be closely related to the visual analog
scale score for pain and response to conventional treatment for IC/
BPS. Several studies have shown that injections of botulinum toxin
A reduce bladder pain in patients with refractory IC/BPS,57,58 and
the increased NGF levels in the bladder tissue of patients with IC/
BPS can decrease to within the normal range after botulinum toxin
A treatment.59 However, the role of NGF may be due to its associ-
ation with bladder function, as NGF also increases in patients with
other bladder diseases, such as OAB and urinary tract infection.
Although NGF might be able to be developed as an indicator for
treatment, in order to be a sensitive molecular diagnostic tool for
IC/BPS, it is likely that a combination of other urinary or tissue
biomarkers is required.
6. Recent development
6.1. Genetic biomarkers
Several pilot studies have attempted to use microarray tech-
nology to reveal genes involved in the pathobiology underlying IC/
BPS.60,61 The results of these studies are promising, and have
demonstrated through biopsy of bladder tissue that a number of
genes with differential expressions exist between IC/BPS patients
and healthy controls. However, further studies are needed in order
to validate the target genes to enable identiﬁcation of genes that
can be used as new biomarkers of IC/BPS. This also indicates that
the fundamental disease processes of IC/BPS are associated with a
heterogeneous and complicated transcriptional network.
In addition to microarray, high-throughput sequencing tech-
nologies provide new methods for the analysis of gene expression.
With the recent increases in speciﬁcity and sensitivity and a
decrease in cost, RNA sequencing technology has been shown to
improve the accuracy of analysis of differential gene expressions,
especially for low-abundance transcripts.62 Therefore, RNA
sequencing technology may be a better tool for enhanced detection
of differential expression in future studies of IC/BPS. These gene
expression-based predictive models can narrow down the number
of potential biomarkers to be studied and their roles of importance
in the disease.
6.2. Reclassiﬁcation of IC/BPS
Recently, researchers have suggested that IC/BPS should be
reclassiﬁed. ESSIC is classiﬁed into several subtypes.63 Elucidatingtial cystitis or bladder pain syndrome (IC/BPS) shows signiﬁcantly increased density in
ntrol was localized to apical urothelial cells (C) 200.
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instance, Logadottir et al64 studied biopsies from patients with
ESSIC Type 3C, and found that the expressions of IL-6, IL-10, and IL-
17A, and inducible nitric oxide synthase mRNA, were signiﬁcantly
higher in the patients than in healthy controls. Another study took
clinical presentation into consideration, and found that several
genes are correlated with clinical factors.60 Nickel et al65 also pro-
posed that a phenotype-directed therapeutic approach can signif-
icantly improve the treatment outcome. Homma and colleagues66
showed that there are different gene expression patterns for
classic and nonclassic IC. Tripp and coworkers67 developed a sys-
tem to classify IC/BPS into several pain-location phenotypes, and
suggested that the system can enable patients to receive better
treatment as it can provide improved pain management.
Therefore, a larger patient sample that can be subclassiﬁed into
different types will help to identify reliable biomarkers for IC/BPS.
In combination with consideration of disease progress and clinical
factors, a noninvasive method can be developed to analyze the
efﬁciency of treatment.7. Conclusion
Abnormal expressions of several bladder epithelial markers,
including mast cells, epithelial differentiation proteins, cell mem-
brane proteins, neurotransmitters, and cytokines, are present in IC/
BPS. Clinical and experimental data have indicated a direct link
between increased levels of NGF in the bladder tissue and urine and
painful inﬂammatory conditions in IC/BPS. However, NGF is not the
only protein that contributes to IC/BPS; therefore, a combination
test withmeasurement of other inﬂammatory proteins in the urine,
or other marker(s) in tissue specimens, is required. Because the
urinary NGF level can also be increased in many lower urinary tract
diseases, such as stones, tumors, acute bacterial infection, as well as
in IC/PBS, it is important to exclude these diseases. Current ﬁndings
suggest that the urinary NGF level can be monitored as a biomarker
for IC/PBS severity and for the response of patients to treatment.
Several recently identiﬁed cytokines and mediators identiﬁed to be
associated with the disease can be useful tools to assess treatment
outcome. Further studies and subclassiﬁcation of IC/PBS are
required to identify new biomarkers for diagnosis, as well as for
treatment efﬁciency in patients with IC/PBS.Conﬂicts of interest
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